DURECT Investor Relations Material
Latest events
Q4 2024
DURECT
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from DURECT Corp
Access all reports
DURECT Corp is a biopharmaceutical company engaged in the development of therapies using epigenetic modulation for the treatment of acute organ injury and chronic liver diseases. Its research focuses on new chemical entities, with a significant emphasis on its endogenous epigenetic regulator program. The company's pipeline includes products such as DUR-928, aimed at conditions like alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, designed for post-operative pain management; and Oradur, for chronic pain and attention deficit hyperactivity disorders. Additionally, DURECT manufactures and markets osmotic pumps for laboratory research and provides biodegradable polymers and excipients for the pharmaceutical and medical device industries. The company is headquartered in Cupertino, California, and its shares are listed on the Nasdaq.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
DRRX
Country
🇺🇸 United States